Composition and method for cancer treatment

Abstract

Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.

1 - 54 . (canceled) 
     
     
         55 . A method of treating brain cancer, prostate cancer, liver cancer, and/or kidney cancer, comprising administering an effective amount of an anti-CEACAM6 antibody or antibody fragment thereof comprising all six of the CDRs of monoclonal antibody 13.1 to a patient with brain cancer, prostate cancer, liver cancer, and/or kidney cancer, wherein the antibody or antibody fragment induces apoptosis in cancer cells. 
     
     
         56 . The method of  claim 55 , wherein the antibody or antibody fragment thereof induces apoptosis against cancer cells in the Cellular Cytotoxicity Assay described herein. 
     
     
         57 . The method of  claim 55 , which is a method of treating brain cancer. 
     
     
         58 . The method of  claim 55 , which is a method of treating prostate cancer. 
     
     
         59 . The method of  claim 55 , which is a method of treating liver cancer. 
     
     
         60 . The method of  claim 55 , which is a method of treating lung cancer. 
     
     
         61 . The method of  claim 55 , wherein the antibody or antibody fragment thereof is humanized. 
     
     
         62 . The method of  claim 55 , wherein the antibody or antibody fragment thereof is chimeric. 
     
     
         63 . The method of  claim 55 , wherein said antibody or antibody fragment thereof is an antibody fragment, and the antibody fragment is an ScFv. 
     
     
         64 . The method of  claim 63 , wherein the ScFv is murine or humanized. 
     
     
         65 . The method of  claim 55 , wherein the patient is a human or a non-human animal. 
     
     
         66 . The method of  claim 55 , wherein the patient is a human. 
     
     
         67 . The method of  claim 66 , wherein the antibody or antibody fragment thereof is administered parenterally, intraperitoneally, intravenously, subcutaneously, orally, nasally, via inhalation or rectally. 
     
     
         68 . The method of  claim 55 , wherein the antibody or antibody fragment thereof is administered intravenously at a dosage of from 5 mg/m 2  to 2000 mg/m 2 . 
     
     
         69 . The method of  claim 55 , wherein the antibody or antibody fragment thereof is monoclonal antibody 13.1.